- Home
- VMO vs AVTX Comparison
VMO vs AVTX Comparison
Compare VMO & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMO | AVTX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 642.0M | 710.1M |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VMO | AVTX |
|---|---|---|
| Price | $8.90 | $6.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $36.60 |
| AVG Volume (30 Days) | 378.2K | ★ 2.4M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $8.12 | $6.53 |
| 52 Week High | $10.10 | $24.27 |
Technical Indicators
Market Signals| Indicator | VMO | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 17.14 |
| Support Level | $8.12 | N/A |
| Resistance Level | $9.84 | $20.54 |
| Average True Range (ATR) | 0.16 | 0.88 |
| MACD | 0.06 | -0.48 |
| Stochastic Oscillator | 90.22 | 3.77 |
Price Performance
Historical ComparisonAbout VMO Invesco Municipal Opportunity Trust
Invesco Municipal Opportunity Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.